Terrance  Mcguire net worth and biography

Terrance Mcguire Biography and Net Worth

Mr. McGuire brings over 35 years of biotechnology venture capital experience as co-founder and general partner of Polaris Partners, where he has provided early stage funding and leadership counsel for over 80 medical and information technology companies. Prior to starting Polaris Partners, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical and information technology companies.  Mr. McGuire currently serves on the boards of Adimab and Alector.  He is a member of the boards of The Thayer School of Engineering at Dartmouth College, The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire has previously served on the boards of Cubist Pharmaceuticals, Acceleron Pharma, Arsanis, and Pulmatrix, among others. Mr. McGuire was formerly chair of the National Venture Capital Association.  In 2020, he was honored by the NVCA with the Outstanding Service Award.  In 2015, Mr. McGuire was listed as one of Scientific American’s Worldview 100 visionaries who continue to reshape biotechnology and the world. He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem. He was awarded honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science. Mr. McGuire earned a B.S. in physics and economics from Hobart College, an M.S. in engineering from The Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.

What is Terrance Mcguire's net worth?

The estimated net worth of Terrance Mcguire is at least $1,766.40 as of August 9th, 2023. Mr. Mcguire owns 552 shares of Cyclerion Therapeutics stock worth more than $1,766 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Mcguire may own. Learn More about Terrance Mcguire's net worth.

How do I contact Terrance Mcguire?

The corporate mailing address for Mr. Mcguire and other Cyclerion Therapeutics executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Cyclerion Therapeutics can also be reached via phone at (857) 327-8778 and via email at [email protected]. Learn More on Terrance Mcguire's contact information.

Has Terrance Mcguire been buying or selling shares of Cyclerion Therapeutics?

Terrance Mcguire has not been actively trading shares of Cyclerion Therapeutics during the last quarter. Most recently, Terrance Mcguire sold 8 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $3.40, for a transaction totalling $27.20. Following the completion of the sale, the director now directly owns 552 shares of the company's stock, valued at $1,876.80. Learn More on Terrance Mcguire's trading history.

Who are Cyclerion Therapeutics' active insiders?

Cyclerion Therapeutics' insider roster includes Peter Hecht (CEO), and Terrance Mcguire (Director). Learn More on Cyclerion Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclerion Therapeutics?

In the last twelve months, insiders at the sold shares 1 times. They sold a total of 8 shares worth more than $27.20. The most recent insider tranaction occured on August, 9th when Director Terrance Mcguire sold 8 shares worth more than $27.20. Insiders at Cyclerion Therapeutics own 13.1% of the company. Learn More about insider trades at Cyclerion Therapeutics.

Information on this page was last updated on 8/9/2023.

Terrance Mcguire Insider Trading History at Cyclerion Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2023Sell8$3.40$27.20552View SEC Filing Icon  
6/3/2021Buy4,807$62.40$299,956.80552View SEC Filing Icon  
See Full Table

Terrance Mcguire Buying and Selling Activity at Cyclerion Therapeutics

This chart shows Terrance Mcguire's buying and selling at Cyclerion Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclerion Therapeutics Company Overview

Cyclerion Therapeutics logo
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.20
Low: $3.20
High: $3.45

50 Day Range

MA: $3.09
Low: $2.78
High: $3.94

2 Week Range

Now: $3.20
Low: $1.75
High: $9.60

Volume

18,636 shs

Average Volume

2,989 shs

Market Capitalization

$8.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83